Progress of immune checkpoint inhibitors in gastric cancer

Table 3 Clinical trials of immune checkpoint inhibitors combined with chemotherapy for gastric cancer

Immune checkpoint inhibitor	Medication regimen	Type of GC	Phase	Clinical trials
Camrelizumab	Combined with chemotherapy (oxaliplatin, paclitaxel)	HER-2 negative, unresectable GC with programmed death ligand 1 + combined positive score ≥ 1, MSI-H/dMMR, or EBV (+) GC	Completed	NCT04694183
Sintilimab	Combined with Apatinib and chemotherapy (S-1 fluoropyrimidine, nab-paclitaxel)	Unresectable patients with stage IV GC	II	NCT04267549
Nivolumab/Pembrolizumab/Atezolizumab	Combined with chemotherapy (cyclophosphamide and fludarabine)	Advanced relapse or progression of solid tumor	I	NCT03841110
Tislelizumab	Combined with Apatinib and chemotherapy (oxaliplatin and capecitabine)	Advanced HER-2-negative GC/GEJ with signet ring cell carcinoma or peritoneal metastasis and poor prognosis	Completed	NCT06238752
Pembrolizumab	HER-2 negative group: Combined with capecitabine/oxaliplatin. HER-2 positive group: Combined with Trastuzumab and capecitabine/cisplatin	EBV negative advanced GC/GEJ and microsatellite-stable (or mismatch repair-proficient) GC	II	NCT04249739
Margetuximab/Retifanlimab/Tebotelimab	Combined with chemotherapy, chemotherapy: Capecitabine and oxaliplatin or mFOLFOX6	HER-2-positive GC/GEJ	III	NCT04082364
Camrelizumab	Combined with FOLFOX	Advanced GC/GEJ	II	NCT03939962
Atezolizumab	Combined with docetaxel, oxaliplatin, and capecitabine	Resectable GC/GEJ	II	NCT03448835
Pembrolizumab	Combined with mFOLFOX6	Potentially resectable locally advanced GC/GEJ (T1N1-3M0 or T2-3NanyM0)	II	NCT03488667
Atezolizumab	Combined with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine)	Previously untreated localized GC/GEJ with MSI-H/dMMR	II	NCT05836584
Avelumab	Combined with peri-operative FLOT	Stage Ib (T1N1 only)-IIIC GC	III	NCT03979131
Avelumab	Combined with FLOT	Resectable GC/GEJ	II	NCT03399071
Atezolizumab	Combined with FLOT	Locally advanced, resectable GC/GEJ without distant metastases	II/III	NCT03421288

EBV: Epstein-Barr virus; FLOT: Docetaxel, oxaliplatin, fluorouracil/Leucovorin; FOLFOX: Folinic acid, fluorouracil, and oxaliplatin; GC: Gastric cancer; GC/GEJ: Gastric cancer/gastroesophageal junction; HER-2: Human epidermal growth factor receptor 2; MSI-H/dMMR: Microsatellite instability-high/DNA mismatch repair.